Does intermittent hemodialysis (HD) in a patient with Chronic Kidney Disease (CKD) stage 4 who develops Acute Kidney Injury (AKI) increase the risk of progression to End-Stage Renal Disease (ESRD), and if so, what is the most likely mechanism?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Intermittent Hemodialysis in CKD Stage 4 with AKI: Risk for ESRD Progression

Intermittent hemodialysis treatments in a patient with CKD stage 4 who develops AKI likely increase the risk of progression to ESRD through mechanisms of maladaptive repair and renal tubular injury. This risk is supported by evidence showing that AKI events in patients with pre-existing CKD significantly accelerate progression to end-stage disease.

Risk of Progression to ESRD

Evidence for Increased Risk

  • Patients who progress from CKD stage 3 to stage 4 already have significantly higher adjusted risks of death (HR = 2.56), AKI (HR = 2.32), and hospitalization (HR = 1.87) prior to developing ESRD 1
  • AKI events, even when followed by apparent recovery, are established risk factors for future development of CKD and progression to ESRD 2
  • The need for RRT during an AKI episode in patients with pre-existing kidney disease is associated with poorer renal outcomes and increased risk of permanent dialysis dependence 3

Mechanisms of Progression

The most likely mechanisms by which intermittent hemodialysis during AKI accelerates progression to ESRD include:

  1. Maladaptive Repair Processes:

    • Repeated kidney injury triggers pathological repair mechanisms that lead to fibrosis rather than restoration of normal tissue 2, 4
    • Cell cycle arrest in the G2/M phase of renal tubular cells promotes a pro-fibrotic phenotype
    • Persistent chronic inflammation following AKI contributes to ongoing kidney damage
  2. Hemodynamic Instability:

    • Rapid fluid shifts during intermittent hemodialysis can cause hypotension
    • Recurrent hypotensive episodes during dialysis may cause repeated ischemic injury to already compromised kidneys
    • Microvascular rarefaction following initial injury reduces perfusion to nephrons
  3. Accelerated Loss of Residual Function:

    • Intermittent hemodialysis may accelerate the decline in residual kidney function 5
    • KDOQI guidelines note that home long frequent hemodialysis can accelerate decline in residual kidney function 5
  4. Inflammatory Cascade:

    • Blood-membrane interactions during hemodialysis activate inflammatory pathways
    • Cytokine release and oxidative stress contribute to ongoing tubular injury
    • Endothelial dysfunction persists after the initial AKI episode

Clinical Management Considerations

Nephrology Consultation

  • KDOQI guidelines recommend that patients who reach CKD stage 4 should receive education about kidney failure and treatment options 5
  • Consultation with a nephrologist when stage 4 CKD develops has been found to reduce cost, improve quality of care, and delay dialysis 5

Modality Considerations

  • The choice between continuous renal replacement therapy (CRRT) and intermittent hemodialysis may impact outcomes, though evidence is mixed
  • Some research suggests that CRRT may be associated with better renal recovery rates at 90 days compared to intermittent hemodialysis (75.4% vs 66.6%), though this difference diminishes by 365 days 6
  • When choosing RRT modality, hemodynamic stability should be a primary consideration 6

Prevention Strategies

  • Careful management of volume status and blood pressure is critical
  • KDOQI guidelines recommend both reducing dietary sodium intake and adequate sodium/water removal to manage hypertension and hypervolemia 5
  • Consider additional hemodialysis sessions or longer treatment times for patients with large weight gains or high ultrafiltration rates 5

Monitoring and Follow-up

For patients with CKD stage 4 who have experienced AKI requiring hemodialysis:

  • Monitor for metabolic acidosis with serum bicarbonate concentration at least every three months 5
  • Measure serum calcium and phosphorus at least every three months 5
  • Assess blood pressure control with target levels <140/90 mmHg to slow CKD progression 5
  • Consider more frequent follow-up due to higher recurrence risk of AKI 7

In conclusion, while intermittent hemodialysis is often necessary to manage AKI in patients with CKD stage 4, clinicians should be aware of the increased risk for progression to ESRD and implement strategies to mitigate this risk through careful monitoring and management of modifiable risk factors.

References

Research

Progression to Stage 4 chronic kidney disease and death, acute kidney injury and hospitalization risk: a retrospective cohort study.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2016

Research

Acute Kidney Injury to Chronic Kidney Disease Transition.

Contributions to nephrology, 2018

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Modality of RRT and Recovery of Kidney Function after AKI in Patients Surviving to Hospital Discharge.

Clinical journal of the American Society of Nephrology : CJASN, 2016

Guideline

Management of Diverticulosis and Acute Gastrointestinal Bleeding in Patients with Chronic Kidney Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.